Pharmaceutical

How to get rid of sulfur burps instantly? Hydrogen sulfide Comparison How to get rid of sulfur burps instantly? Hydrogen Sulfide (H₂S) is a colorless gas with a strong odor of rotten eggs. It is primarily used in industrial processes such as petroleum refining and natural gas processing, but can cause sulfur burps when produced in excess in the digestive system.
Is Tadalafil Better Than Sildenafil? Tadalafil Sildenafil Comparison Is Tadalafil better than Sildenafil? Tadalafil is effective for daily use in treating erectile dysfunction and benign prostatic hyperplasia, while Sildenafil is typically taken on-demand for erectile dysfunction. Consider your needs for the best choice.
Atropine vs Adenosine Atropine Adenosine Comparison Atropine vs Adenosine: Atropine is used to treat bradycardia and to reduce saliva production during surgery, while Adenosine is employed to manage certain types of arrhythmias and regulate heart rate. Find out which medication is right for your condition.
D glucose vs L glucose D-glucose L-glucose Comparison D glucose vs L glucose: D-Glucose is the naturally occurring form of glucose used by the body for energy, while L-Glucose is its mirror image and has limited biological activity. Discover the differences and uses of these isomers.
GSK IBAT Inhibitor Treatment for PBC-Related Cholestatic Pruritus Phase III Study Success GSK GSK announces positive Phase III results for Linerixibat, an IBAT inhibitor, in treating cholestatic pruritus associated with PBC, showing significant symptom improvement and promising safety data.
MK-3475A-D77 Study Success Merck Merck's Phase III MK-3475A-D77 study shows positive results for subcutaneous pembrolizumab (MK-3475A) compared to intravenous Keytruda, improving patient experience and accessibility for metastatic NSCLC treatment.
Capital Trend! $16.9 Billion Pharma Spin-off Sanofi Sanofi is negotiating the sale of a 50% stake in its consumer health unit Opella to Clayton, Dubilier & Rice for $16.9 billion. Learn more about the spin-off and other recent pharma industry trends.
Johnson & Protagonist's Oral IL23 Psoriasis Phase 3 Success Johnson & Johnson Protagonist therapeutics Johnson & Johnson and Protagonist announce positive Phase 3 results for Icotrokinra (JNJ-2113), an oral IL-23 receptor antagonist for moderate-to-severe plaque psoriasis, achieving significant skin clearance and a $165M milestone payment.
BeiGene and MSN Pharmaceuticals Settle Patent Lawsuit on Zanubrutinib Generic BeiGene BeiGene and MSN Pharmaceuticals settle patent lawsuit over Zanubrutinib generic, extending patent protection until 2037. The settlement reaffirms BeiGene’s confidence in protecting its groundbreaking BTK inhibitor.
Myopia Eye Drop Phase III Study Fails Eyenovia Eyenovia's Phase III CHAPERONE study of MicroPine to delay myopia progression in children fails to meet its primary endpoint, causing a 70% drop in the company's stock price. CEO discusses next steps and strategic options.